AMD Clinical Trial
Official title:
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Recruiting |
NCT03893474 -
Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
|
N/A | |
Completed |
NCT00971464 -
Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation
|
Phase 2 | |
Terminated |
NCT00332657 -
Anecortave Acetate Risk Reduction Trial (AART)
|
Phase 3 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT01766596 -
Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)
|
N/A | |
Completed |
NCT03322930 -
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
|
||
Completed |
NCT01778491 -
AMD Phenotype and Genotype Study
|
||
Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
Active, not recruiting |
NCT03845582 -
Phase 3 Study of ALK-001 in Geographic Atrophy
|
Phase 3 | |
Completed |
NCT03367767 -
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
|
||
Completed |
NCT03372746 -
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
|
||
Terminated |
NCT00333216 -
Anecortave Acetate Risk-Reduction Trial (AART)
|
Phase 3 | |
Completed |
NCT01570790 -
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00726466 -
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
|
Phase 1 | |
Completed |
NCT00306488 -
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
|
Phase 2 | |
Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01632527 -
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A | |
Recruiting |
NCT03675880 -
TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects
|
Phase 1 |